View on GitHub

Pistoia-Alliance-PGO

Pistoia Alliance Pharma General Ontology - One, shared and maintained upper level reference ontology for Pharma.

Class: Drug

Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances. https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:23888

Alternative Descriptions * alt_description_text | | * alt_description_source | | * MESH | |
Aliases * Drug Product
Examples | Value | Description | | --- | --- | | [morphine](http://purl.obolibrary.org/obo/CHEBI_17703) | morphine is a common drug used to treat severe pain | | [aspirin](http://purl.obolibrary.org/obo/CHEBI_15365) | aspirin is a common drug used to reduce pain, fever, or inflammation | | [Ibuprofen](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5855) | an example of a protein belonging to the cadherin family | | [Albuterol](https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2550) | a common drug used to treat asthma and other respiratory conditions |
Annotations | property | value | | --- | --- | | definition_source | https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:23888 | | definition_source_attribution | Chemical Entities of Biological Interest (ChEBI) | | definition_source_licence | [CC-BY-4.0](https://creativecommons.org/licenses/by/4.0/) | | definition_access_date | 2025-06-09 | | expert_approval_date | 2025-06-12 | | conceptual_clarification | * CHEBI_23888-- Used in chemical biology, this definition is chemically precise and versatile but lacks explicit mention of therapeutic intent. While it offers a good balance of broadness and precision, some critique its inclusion of 'abused substances' and the absence of use-purpose, which could cause ambiguity in regulatory and clinical contexts. Despite this, it remains a strong candidate for use, especially as a short-form, ontology-aligned option. * NCIT_C1909 (Pharmacologic Substance)-- Defined by the National Cancer Institute Thesaurus (NCIT), this term is widely used in oncology and pharmacology. It is comprehensive for cancer-related substances and integrates 'drug' as an alternative label. Reviewers noted it provides a good balance between specificity and breadth, making it a preferred choice for contexts demanding clarity and precision. However, some flagged its verbose hierarchy as potentially cumbersome for practical integration. * DRON_00000005 (Drug Product, Drug Ontology)-- This definition is very precise, focusing specifically on the product-level aspects of drugs, including dosage forms, routes of administration, and packaging. While useful in pharmaceutical manufacturing contexts, its narrow scope and conflation of 'product' may be too limiting or confusing for broader biomedical applications. * BioLink Model-- Drug-- Compatible with the FDA’s regulatory definition, this term emphasizes intentional therapeutic use, diagnosis, and structural/function modification, excluding devices. It provides a clear framework aligned with legal and clinical standards. This definition is useful in translational research and regulatory informatics, but some members found it too narrow, particularly in terms of broader biomedical data modeling. * Schema.org Drug-- Designed primarily for web-based medical schemas, this definition was considered redundant and less precise than alternatives like NCIT_C1909. Its narrow utility and alignment with 'medical therapy' contexts limit its applicability for comprehensive biomedical modeling. |
Comments * The expert group has undertaken a comparative analysis of existing ontological and semantic representations of the term 'drug', highlighting its definitional complexity and contextual variability across biomedical domains. While the term is widely used, it lacks a universally accepted definition that captures both its pharmacological characteristics and the intentionality of use (e.g., therapeutic, performance-enhancing, diagnostic). The discussion emphasizes that the concept of 'drug' may evolve depending on the stage of the biomedical pipeline (e.g., research, development, regulatory submission, post-market surveillance), and is often embodied in physical products containing active substances. * Several reference models and ontologies were reviewed * CHEBI_23888-- Used in chemical biology, this definition is chemically precise and versatile but lacks explicit mention of therapeutic intent. While it offers a good balance of broadness and precision, some critique its inclusion of 'abused substances' and the absence of use-purpose, which could cause ambiguity in regulatory and clinical contexts. Despite this, it remains a strong candidate for use, especially as a short-form, ontology-aligned option. * NCIT_C1909 (Pharmacologic Substance)-- Defined by the National Cancer Institute Thesaurus (NCIT), this term is widely used in oncology and pharmacology. It is comprehensive for cancer-related substances and integrates 'drug' as an alternative label. Reviewers noted it provides a good balance between specificity and breadth, making it a preferred choice for contexts demanding clarity and precision. However, some flagged its verbose hierarchy as potentially cumbersome for practical integration. * DRON_00000005 (Drug Product, Drug Ontology)-- This definition is very precise, focusing specifically on the product-level aspects of drugs, including dosage forms, routes of administration, and packaging. While useful in pharmaceutical manufacturing contexts, its narrow scope and conflation of 'product' may be too limiting or confusing for broader biomedical applications. * BioLink Model-- Drug-- Compatible with the FDA’s regulatory definition, this term emphasizes intentional therapeutic use, diagnosis, and structural/function modification, excluding devices. It provides a clear framework aligned with legal and clinical standards. This definition is useful in translational research and regulatory informatics, but some members found it too narrow, particularly in terms of broader biomedical data modeling. * Schema.org Drug-- Designed primarily for web-based medical schemas, this definition was considered redundant and less precise than alternatives like NCIT_C1909. Its narrow utility and alignment with 'medical therapy' contexts limit its applicability for comprehensive biomedical modeling. * Further, several PGO Core Concepts (Compound, Product) are noted as closely related to 'drug' but do not fully resolve its semantic ambiguity. The group acknowledges the importance of aligning terminology across related concepts while striving for definitional clarity. * Recommendation to the PGO Steering group-- 1. The experts team recommends adopting CHEBI_23888 as the working definition of 'drug' within the Pharma General Ontology. This term provides a widely accepted and practical balance between generality and specificity for use in life sciences and pharmaceutical contexts. 2. However, it is also recommended that 2a The limitations of the CHEBI_23888 definition around _intentionality and therapeutic purpose_ be explicitly noted. *2b 'Drug' be treated as a synonym for more specific terms such as 'pharmacologic substance' (NCIT_C1909) when contextual clarity is required. *2c A future proposal may be submitted to CHEBI to revise or clarify the definition to better accommodate contextual and regulatory dimensions.
TODOs ## TODOs * Review preferred sources